Wed. 20 Mar 2024, 7:13am ET
Benzinga
Earnings, News
LAVA Therapeutics (NASDAQ:LVTX) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.12) by 100 percent. This is a 57.89 percent increase over losses of $(0.57) per share from the same period last year. The company reported quarterly sales of $353.00 thousand which missed the analyst consensus estimate of $6.25 million by 94.35 percent. This is a 86.63 percent decrease over sales of $2.64 million the same period last year.